Abstract: Ovarian cancer is one of the three major malignant tumors common in female genitalia. Because the ovary is located in the deep pelvic cavity, the onset is concealed. About 70%-75% of patients have reached the advanced stage when symptoms appear, which seriously threatens women′s health. Most of the ovarian cancer susceptibility genes currently known play a role in repairing DNA double-strand breaks by homologous recombination: BRCA1 and BRCA2 are the two most common genes in ovarian cancer, which are the key factors in the process of homologous recombination repair of double-stranded DNA breaks. The multiple pathogenic mutations in the BRCA tumor suppressor network with its core composition can damage the integrity and stability of genomics and increase the susceptibility of ovarian cancer. A number of studies have shown that the expression of homologous recombination-related genes or proteins is related to the sensitivity of tumors to radiotherapy and genotoxic drugs, and can be used as a biomarker for individualized treatment of tumors. In this paper, the relationship between several important gene mutations closely related to ovarian cancer in the homologous recombination repair pathway and ovarian cancer is discussed, which lays a clinical foundation for the screening and early prevention of ovarian cancer.

Key words: Ovarian neoplasms, Homologous recombination, Recombination, genetic, Gene mutation, Precise treatment